Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.22.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 5,897 $ 14,660
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 5,897 14,660
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,165 1,239
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,064 11,883
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,897 220
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 771 1,318
BMS Agreement and the 2018 BMS Master Services Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 2,165 1,239
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 244 302
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 1,921 937
2020 Merck Master Services Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,064 11,883
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 862 9,061
2020 Merck Master Services Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 173 1,205
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   231
2020 Merck Master Services Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 29 1,386
2019 EMD Serono Supply Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,897 220
2019 EMD Serono Supply Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 284 163
2019 EMD Serono Supply Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,613 57
Supply Agreement | Vaxcyte, Inc.    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 771 1,318
Supply Agreement | Vaxcyte, Inc. | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 601 205
Supply Agreement | Vaxcyte, Inc. | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 170 $ 1,113